三生制药(01530.HK) 公布，与全资附属沈阳三生及辉瑞(PFE.US) 于昨日(19日)订立独家许可协议，将向辉瑞授予独家许可，以在中国内地以外的全球地区开发、生产、商业化及以其他方式开发其突破性PD-1/VEGF双特异性抗体(SSGJ-707)。
三生制药及沈阳三生将保留许可产品于中国内地的开发、制造、商业化及其他开发权，辉瑞则拥有在中国商业化许可产品的选择权。许可首付款为12.5亿美元，公司并可获得高达48亿美元的潜在付款，包括开发、监管批准及销售里程碑付款，另将就许可地区的产品净销售额收取双位数百分比的梯度特许权使用费。
于许可协议生效日期，辉瑞将根据股份认购协议，按30日成交量加权平均价认购三生制药价值1亿美元的普通股。公司将向辉瑞配发及发行新股份，确切条款及数目将于正式协议中厘定及最终确定。(gc/w)(港股报价延迟最少十五分钟。沽空资料截至 2025-05-19 16:25。) (美股为即时串流报价； OTC市场股票除外，资料延迟最少15分钟。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.